Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


29.10.2018

1 Ann Neurol
1 Curr Treat Options Neurol
1 J Clin Psychopharmacol
1 J Neural Transm (Vienna)
2 J Neurol Neurosurg Psychiatry
1 Lancet
7 Mov Disord
2 Neurol Genet
3 Neurology
1 Neuropsychology
1 Neurosci Lett
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Neurol

  1. ESPAY AJ, Morgante F, Merola A, Fasano A, et al
    Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts.
    Ann Neurol. 2018 Oct 24. doi: 10.1002/ana.25364.
    PubMed     Text format     Abstract available


    Curr Treat Options Neurol

  2. PFEIFFER RF
    Gastrointestinal Dysfunction in Parkinson's Disease.
    Curr Treat Options Neurol. 2018;20:54.
    PubMed     Text format     Abstract available


    J Clin Psychopharmacol

  3. WARNER CB, Ottman AA, Brown JN
    The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review.
    J Clin Psychopharmacol. 2018 Oct 19. doi: 10.1097/JCP.0000000000000963.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  4. RICCIARDI L, Visco-Comandini F, Erro R, Morgante F, et al
    Emotional facedness in Parkinson's disease.
    J Neural Transm (Vienna). 2018 Oct 20. pii: 10.1007/s00702-018-1945.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  5. MARTINEZ-CASTRILLO JC
    Impulse control disorders in Parkinson's disease: a hard-turning point.
    J Neurol Neurosurg Psychiatry. 2018 Oct 25. pii: jnnp-2018-319375.
    PubMed     Text format    

  6. LEE JY, Jeon B, Koh SB, Yoon WT, et al
    Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    J Neurol Neurosurg Psychiatry. 2018 Oct 25. pii: jnnp-2018-318942.
    PubMed     Text format     Abstract available


    Lancet

  7. WEBSTER P
    Pimavanserin evaluated by the FDA.
    Lancet. 2018;391:1762.
    PubMed     Text format    


    Mov Disord

  8. BETROUNI N, Delval A, Chaton L, Defebvre L, et al
    Electroencephalography-based machine learning for cognitive profiling in Parkinson's disease: Preliminary results.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27528.
    PubMed     Text format     Abstract available

  9. HUANG X, Ng SY, Chia NS, Acharyya S, et al
    Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27521.
    PubMed     Text format    

  10. HABETS JGV, Heijmans M, Kuijf ML, Janssen MLF, et al
    An update on adaptive deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Oct 24. doi: 10.1002.
    PubMed     Text format     Abstract available

  11. TRINH J, Zeldenrust FMJ, Huang J, Kasten M, et al
    Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Mov Disord. 2018 Oct 24. doi: 10.1002/mds.27527.
    PubMed     Text format     Abstract available

  12. WAGLE SHUKLA A, Fox SH
    Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
    Mov Disord. 2018;33:1560.
    PubMed     Text format    

  13. SCHRAG A
    Testing the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018;33:1518-1520.
    PubMed     Text format    

  14. DULOVIC M, Vos M
    Sleep dysfunction in Parkinson's disease: Novel molecular mechanism and implications for therapy.
    Mov Disord. 2018;33:1558-1559.
    PubMed     Text format    


    Neurol Genet

  15. WALLEN ZD, Chen H, Hill-Burns EM, Factor SA, et al
    Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.
    Neurol Genet. 2018;4:e271.
    PubMed     Text format     Abstract available

  16. LEE RG, Sedghi M, Salari M, Shearwood AJ, et al
    Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction.
    Neurol Genet. 2018;4:e276.
    PubMed     Text format     Abstract available


    Neurology

  17. KARAM C, Galetta S
    Editors' note: The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease.
    Neurology. 2018;91:810.
    PubMed     Text format    

  18. VAN GERPEN JA, Tipton PW, Uitti RJ
    Reader response: The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease.
    Neurology. 2018;91:810-811.
    PubMed     Text format    

  19. FERRAYE MU
    Author response: The laser shoes: A new ambulatory device to alleviate freezing of gait in Parkinson disease.
    Neurology. 2018;91:811.
    PubMed     Text format    


    Neuropsychology

  20. PETKUS AJ, Filoteo JV, Schiehser DM, Gomez ME, et al
    Worse cognitive performance predicts increased anxiety and depressive symptoms in patients with Parkinson's disease: A bidirectional analysis.
    Neuropsychology. 2018 Oct 18. pii: 2018-52387-001. doi: 10.1037/neu0000498.
    PubMed     Text format     Abstract available


    Neurosci Lett

  21. MIRANDA-MORALES EG, Sandoval-Carrillo A, Castellanos-Juarez FX, Mendez-Hernandez EM, et al
    H1/H2 MAPT haplotype and Parkinson's Disease in Mexican mestizo population.
    Neurosci Lett. 2018 Oct 16. pii: S0304-3940(18)30705.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  22. GUO JF, Zhang L, Li K, Mei JP, et al
    Coding mutations in NUS1 contribute to Parkinson's disease.
    Proc Natl Acad Sci U S A. 2018 Oct 22. pii: 1809969115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: